NEFL and myeloid sarcoma: Ibudilast 100 mg/kg in progressive multiple sclerosis (MS) patients did not reduce serum nor cerebrospinal fluid neurofilament light chain levels (Fox et al., 2021) Ibudilast did not attenuate focal inflammation pathology in progressive MS but had neuroprotective effect (Goodman et al., 2021)